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Abstract:  Deleted  in  Malignant  Brain  Tumors-1  protein  (DMBT1),  salivary  agglutinin 
(DMBT1
SAG), and lung glycoprotein-340 (DMBT1
GP340) are three names for glycoproteins 
encoded by the same DMBT1 gene. All these proteins belong to the scavenger receptor 
cysteine-rich  (SRCR)  superfamily  of  proteins:  a  superfamily  of  secreted  or  
membrane-bound proteins with SRCR domains that are highly conserved down to sponges, 
the most ancient metazoa. In addition to SRCR domains, all DMBT1s contain two CUB 
domains and one zona pellucida domain. The SRCR domains play a role in the function of 
DMBT1s,  which  is  the  binding  of  a  broad  range  of  pathogens  including  cariogenic 
streptococci, Helicobacter pylori and HIV. Mucosal defense proteins like IgA, surfactant 
proteins and lactoferrin also bind to DMBT1s through their SRCR domains. The binding 
motif on the SRCR domains comprises an 11-mer peptide in which a few amino acids are 
essential for binding (GRVEVLYRGSW). Adjacent to each individual SRCR domain are 
glycosylation domains, where the attached carbohydrate chains play a role in the binding of 
influenza A virus and Helicobacter pylori. The composition of the carbohydrate chains is 
not only donor specific, but also varies between different organs. These data demonstrate a 
role  for  DMBT1s  as  pattern  recognition  molecules  containing  various  peptide  and 
carbohydrate binding motifs.  
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1. Introduction: Saliva as a Protective Fluid 
Mucosal surfaces are the largest and most important interface between the human body and its 
environment, comprising a total area of approximately 300 m
2 [1]. Interaction with the environment is 
of vital importance for the uptake of nutrients and oxygen, but the external interaction of mucosal 
surfaces also poses a threat the body. These threats include antigenic, mitogenic and toxic stimuli in 
food and in the air as well as pathogenic bacteria and viruses. To overcome these constant challenges, 
the immune system has developed extensive innate and adaptive responses.  
The oral tissues, a part of the mucosal immune system, are constantly covered by saliva, which 
harbors a similar set of antimicrobial proteins as other mucosal fluids [2]. A major role of saliva is to 
maintain the natural oral microbial ecosystem. The function and secretion of saliva can be disturbed 
after radiation therapy for head and neck cancer, by auto-immune diseases affecting glandular tissues 
such as Sjögren’s syndrome [3,4] or as a side-effect of numerous drugs. A reduced saliva secretion 
leads to a significant increase in oral bacteria as well as to a shift in composition of the oral microflora. 
At the same time, the oral complications increase in number and severity [5]. Reduced saliva secretion 
may also affect general health. For instance, the majority of sedated patients in intensive-care units 
show a shift in the oral microflora from Gram-positive to Gram-negative species, which subsequently 
may spread into the respiratory tract causing pulmonary afflictions [6].  
2. Adherence and Oral Infections 
As  a  result  of  the  continuous  flow  of  saliva  in  our  mouth,  planktonic  bacteria  are  swallowed, 
making microbial adherence one of the key selective criteria in the oral cavity [7,8]. Salivary proteins 
in solution may inhibit adherence by competition with bacterial binding sites on proteins coated at 
dental surfaces. Binding of salivary proteins to bacteria may result in bacterial agglutination which is, 
therefore,  considered  as  a  mechanism  for  clearance  of  bacteria  and  protection  against  dental  
caries  [9–11].  One  of  the  important  bacteria  agglutinating  proteins  is  Deleted  in  Malignant  Brain 
Tumors-1 protein (DMBT1) also known as Salivary Agglutinin (DMBT1
SAG) [12,13]. 
3.  Deleted  in  Malignant  Brain  Tumors-1  (DMBT1),  Salivary  Agglutinin  (DMBT1
SAG)  and 
Glycoprotein 340 (DMBT1
GP340) 
Streptococcus  mutans  is  considered  the  major  cause  for  dental  caries.  In  search  for  S.  mutans 
agglutinating substances, Ericson and Rundegren isolated a 300–400 kDa glycoprotein from parotid 
saliva [12] that showed calcium-dependent binding to S. mutans. This protein was named salivary 
agglutinin (DMBT1
SAG). It also binds a number of both Gram-positive and Gram-negative bacteria,  
as well as to host proteins including  IgA,  complement factor C1q, bovine and human lactoferrin, 
albumin and lysozyme [14–19]. Several studies have shown that the protein core of DMBT1
SAG is 
identical  with  lung  glycoprotein  340  (DMBT1
GP340)  and  Deleted  in  Malignant  Brain  Tumors-1 
(DMBT1) [20–22]. The amino acid sequences characterized so far are identical to the one deduced 
from the DMBT1 gene [23,24]. DMBT1
SAG and DMBT1
gp-340 cross
 react with monoclonal antibodies 
raised against the DMBT1s isolated from the different sources. Both proteins show calcium-dependent 
binding to S. mutans and SP-D [21]. DMBT1
GP340 was purified from bronchoalveolar lavage fluid of Int. J. Mol. Sci. 2010, 11                       
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patients with alveolar proteinosis [20]. It binds to surfactant proteins A (SP-A) and D (SP-D) [25], 
members of the collectin family that play an important role in innate immunity by binding to specific 
carbohydrate  structures  on  the  surface  of  pathogenic  micro-organisms  [26].  DMBT1
SAG  and 
DMBT1
GP340 thus represent DMBT1 isoforms that are encoded by the DMBT1 gene on chromosome 
10q26.13. The DMBT1 gene shows frequent genomic rearrangements and/or loss of expression in two 
common types of malignant brain tumors, but also in diverse epithelial cancer types, including lung, 
gastric,  esophageal,  colon,  breast,  and  skin  cancer  [27–36].  A  search  through  the  human  genome 
revealed only one copy of the gene. Genetic polymorphism results in variants with different numbers 
of SRCR exons. In addition, different isoforms may arise through alternative splicing or differential 
post-translational modifications such as glycosylation.  
4. The Domain Organization of DMBT1 
The most typical feature of DMBT1 is that it consists of protein domains (Figure 1). DMBT1 is a 
member of the scavenger receptor cysteine-rich (SRCR) superfamily, which is characterized by the 
presence of one or more SRCR domains [23,24]. In between each of the multiple SRCR domains, all 
located to the N-terminal end of the DMBT1s, are short serine-threonine-rich amino acid motifs of  
20–24  amino  acids  in  length,  called  SRCR  interspersed  domains  (SIDs).  The  largest  naturally 
occurring  allele  known  to  date  contains  13  of  these  SRCR-SID  units,  while  the  shortest  known 
displays only eight. This genetic variability in normal individuals raises the question if size variations 
of  DMBT1
GP340,  DMBT1
SAG  and  variants  from  other  tissues  are  due  to  alternative  splicing  and  
post-translational processing or are alternatively determined by genetic differences.  
The stretch of tandem repeated SRCR domains with their interspersed SIDs are followed by two 
CUB  domains  separated  by  a  14th  SRCR  domain,  and  at  the  C-terminal  end  of  the  gene  is  a  
Zona Pellucida domain. Except for the SIDs, these domains are all known to be involved in ligand 
binding [37–39]. DMBT1 orthologs have been identified in various mammalian organisms such as 
mouse (dmbt1,  CRP-ductin, vomeroglandin, muclin,  apactin), rat  (dmbt1, ebnerin, pancrin),  rabbit 
(hensin), cow (bovine gall bladder mucin), pig (dmbt1) and rhesus monkey (H3) (Table 1). These 
proteins all have in common that they consist of SRCR, CUB and ZP domains although the number 
and order of these domains may be different (Figure 1).  
Table 1. DMBT1 synonyms and orthologs in different organisms. 
Organism  Name   Function  
Human  DMBT1 
gp-340 
SAG 
Tumor suppression 
Epithelial cell differentiation 
Innate immunity 
Mouse  CRP-ductin  
Vomeroglandin 
Muclin 
apactin 
Mucosal defense 
Epithelial differentiation 
Pheromone perception 
Sorting receptor 
Rabbit  Hensin  Terminal differentiation of kidney epithelial 
intercalated cells and embryonic stem cells 
Rat  Ebnerin 
Pancrin 
Liver regeneration 
Taste perception Int. J. Mol. Sci. 2010, 11                       
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Table 1. Cont. 
Organism  Name   Function  
Pig  Porcine dmbt1    
Cow  Bovine gallbladder 
mucin 
Cholesterol-binding 
Gallstone formation 
Rhesus monkey  H3  Hormone-responsive 
Endometrial regeneration in ovulation cycle 
Figure  1.  Domain  organization  of  DMBT1  and  DMBT1  orthologs.  This  picture  was 
adapted from J.Mollenhauer [35]. DMBT1/8 kb.2 and DMBT1/6 kb.1 represent the largest 
and the smallest human variant, respectively, that have been recovered so far. The DMBT1 
prototype  features  13  scavenger  receptor  cysteine  rich  (SRCR)  domains,  separated  by 
SIDs. The SRCR domains are followed by a short Thr-rich region, a CUB domain, a 14th 
SRCR domain, a Ser-Thr-Pro-rich region, a second CUB domain, and a Zona Pellucida 
domain. The DMBT1 orthologs from the rabbit (Hensin), Mouse (CRP-ductin-alfa), rat 
(Ebnerin) and pig have varying numbers of SRCR domains, followed by one or more CUB 
domains,  and  share  a  C-terminal  SRCR  domain,  CUB  domains  and  Zona  Pellucida 
domain.  
 Int. J. Mol. Sci. 2010, 11                       
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5. SRCR Domains  
The  most  prevalent  domains  in  DMBT1  are  the  SRCR  domains  [38].  The  SRCR  superfamily 
consists of both membrane bound and secreted proteins which play a role in ligand binding [40]. 
SRCR proteins are present in multicellular animals along the entire animal kingdom, with their earliest 
appearance  in  sponges  [38,41,42].  In  addition,  they  also  appear  in  protozoan  parasites  such  as 
Cryptosporidium, Toxoplasma and Plasmodium and algae of the genus Chlamidomonas [43,44]. The 
organism with the highest number of SRCR domains is the purple sea urchin, Strongylocentrotus 
purpuratus, which contains 218 genes comprising altogether 1,095 SRCR domains [45]. For these 
SRCR proteins, a role as innate immune receptors was suggested since this organism also has a high 
number  of  innate  immune  receptors  such  as  Toll-like  receptors.  Despite  their  presence  in  a  large 
variety of animals [42], SRCR domains have retained a high degree of conservation. SRCR domains 
are ~100–110 amino acids long and can be subdivided into two groups: members of group A contain 
SRCR domains with six cysteine residues, which are encoded by two exons; members of group B, to 
which DMBT1 belongs, usually contain SRCR domains with eight cysteine residues and are encoded 
by a single exon [38]. The position of the cysteines and their disulfide bond pattern are well conserved 
within each SRCR domain. The disulfide bond pattern of a group B SRCR domain is C1–C4, C2–C7, 
C3–C8 and C5–C6 [42].  
6. CUB Domains  
The  CUB  domain  is  a  100–110  residue-spanning  extracellular  domain  named  after  the  three 
proteins,  in  which  it  was  first  recognized:  Complement  subcomponents  (C1s/C1r),  embryonic  sea 
urchin protein (Uegf; sea urchin epidermal growth factor), and bone morphogenetic protein 1 (Bmp1). 
CUB  domains  are  found  in  numerous  proteins  that  are  mainly  involved  in  developmental  
processes [39]. Almost all CUB domains contain four conserved cysteines, which probably form two 
disulfide bridges (C1–C2,  C3–C4). The structure of the CUB domain  has  been predicted to  be a  
beta-barrel similar to that of immunoglobulins [46]. 
7. Zona Pellucida Domains  
The  zona  pellucida  (ZP)  domain  was  first  recognized  in  the  sperm  receptor  proteins  ZP2  and  
ZP3 [39,47]. These proteins are, along with ZP1, responsible for sperm adhesion to the zona pellucida, 
the glycoprotein membrane surrounding the plasma membrane of the oocyte. The ZP domain is a  
~260 amino acid module which contains eight conserved cysteines, forming four disulfide bridges. The 
disulfide bonding pattern suggests that the ZP domain consists of two subdomains. In addition to the 
conserved cysteines, a few aromatic or hydrophobic amino acids are absolutely invariant [48]. ZP 
domains are usually present in glycosylated proteins containing other domains and usually located at 
the C-terminal of the polypeptide, which is also the case for DMBT1s. The functions of proteins 
containing a ZP domain vary tremendously. They are found in glycoproteins involved in development, 
acoustic  perception,  immunity,  and  cancer  [49].  ZP  domains  have  been  suggested  to  play  a  
role  in  protein  oligomerization  [50].  This  is  consistent  with  the  model  that  DMBT1
SAG  forms 
aggregates [51,52].  Int. J. Mol. Sci. 2010, 11                       
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8. Glycosylation Patterns of DMBT1
SAG 
The  carbohydrate  part  of  DMBT1
SAG  accounts  for  25–40%  of  the  molecular  weight  [23,52]. 
DMBT1s  contains  up  to  14  potential  N-linked  glycosylation  sites  [23],  and  numerous  potential  
O-linked sites situated primarily in the SIDs. The SRCR domains, however, contain only few potential 
O-glycosylation sites (Ser and Thr residues). Presumably, the high density of glycans forces the SIDs 
in an extended conformation, as has been demonstrated for mucins [53], thereby creating a molecule 
with alternating stretched SIDs and globular SRCR domains.  
The dominating O-linked structures in DMBT1
SAG are extended core 1 and core 2 oligosaccharides, 
either  neutral  or  monosialylated  (Table  2).  These  structures  are  extended  by  fucosylated  
oligo-N-acetyllactosamine  units.  Sialylation  and  fucosylation  are  found  terminating  the  
N-acetyllactosamine  chains  as  Sialyl-Le
x  or  Le
b/Le
y,  respectively.  Sialylated  structures  tend  to  be 
shorter  than  fucosylated  structures,  suggesting  that  sialylation  regulates  the  N-acetyllactosamine 
extension.  
Glycosylation of proteins is controlled by genetically encoded glycosyltransferases [54]. The Se 
gene,  which  determines  the  presence  of  blood  group  antigens  in  secretory  fluids,  encodes  a  
α1,2-fucosyltransferase. This enzyme couples a fucose to galactose (Fucα1-2Gal), which is the first 
step  in  the  generation  of  blood  group  antigens.  Consequently,  non-secretors  have  a  different 
carbohydrate  composition  compared  to  secretors.  Non-secretors  have  Le
a  and  Le
x  structures  on 
DMBT
SAG;  secretors  also  have  Le
b  and  Le
y  and  ABH  structures,  in  addition  to  Le
a  and  Le
x,  on 
DMBT1
SAG [13,55]. DMBT1
SAG from secretors has a higher molecular mass than DMBT1
SAG from 
non-secretors [55]. Although evidence has been obtained that blood group antigens such as ABH and 
the Le
a antigens function as ligands for bacterial receptors, and thus might be involved in bacterial  
binding  [56–58],  only  a  few  papers  describe  a  correlation  between  blood  group  status  and  the 
susceptibility to caries [59].  
Glycosylation  of  lung  DMBT1
GP340  is  different  from  that  of  salivary  DMBT1
SAG.  Lung 
DMBT1
GP340 completely lacks ABH and Le antigens [55] and its content of 2,3 linked sialic acid 
residues seems to be lower than that of salivary DMBT1
SAG [60]. It is not clear, however, to what 
extent this difference is related to individual variation in glycosylation, as the preparations were from 
different donors. Differences are also found for tear DMBT1 when compared to saliva DMBT1
SAG. In 
contrast to saliva, DMBT1 in tears had no sialyl-Le
x. [61]. 
Also,  time-dependent  variations  in  glycosylation patterns have been reported. The reactivity  of 
DMBT1
SAG with antibody MECA-79, which recognizes the L-selectin ligand SO3-6GlcNAc [62,63], 
fluctuates during the ovulation cycle. It is low shortly after menstruation and reaches a maximum a few 
days after ovulation. Also, during pregnancy and lactation, reactivity is high. These results suggest that 
sulfation of DMBT1
SAG is hormonally regulated [63].  Int. J. Mol. Sci. 2010, 11                       
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Table 2. Overview of glycan chains found on DMBT1. 
Oligosaccharide  Structure  Method  Source  Reference: 
core 1  
sialylated-core 1 
Gal1-3GalNAcα1-Ser/Thr 
NeuAcα2-3 Gal1-3GalNAcα1-Ser/Thr  LC-MS
2  Tears/Saliva  [61,64]  
disialylated-core 1  NeuAc2-3Gal1-3(NeuAc2-6)GalNAcα1-Ser/Thr 
core 2  Gal1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr  LC-MS
2  Tears/Saliva 
[61,64] 
sialylated-core 2  NeuAcα2-3 Gal1-3(GlcNAcβ1-6)GalNAcα1-Ser/Thr 
(Le-a)   Gal1-4(Fuc1-3)GlcNAc  immunoblotting  Saliva  [13] 
(Le-x)   Gal1-3(Fuc1-4)GlcNAc  immunoblotting  Saliva  [13,22] 
(Le-b)   Fuc1-2 Gal1-4(Fuc1-3)GlcNAc  immunoblotting/LC-MS
2  Saliva  [13,64] 
(Le-y)   Fuc1-2Gal1-3(Fuc1-4)GlcNAc  immunoblotting/LC-MS
2  Saliva  [13,64] 
H antigen  
A antigen 
B antigen  
Fuc1-2 Gal1-4GlcNAc  
GalNAc1-3(Fuc1-2 )Gal1-4GlcNAc  
Gal1-3(Fuc1-2 )Gal1-4GlcNAc 
immunoblotting/LC-MS
2 
immunoblotting  
immunoblotting  
Saliva 
Saliva 
Saliva 
[13,64] 
[13] 
[13] 
(Sialyl-Le
x)   NeuA-α2-3Galβ1-3(Fucα1-4)GlcNAc  immunoblotting  saliva, not lung  [22] 
Sialyl-Le
a   NeuAc2-3 Gal1-4(Fuc1-3)GlcNAc  Immunoblotting/LC-MS
2  Tears  [61]]  
  NeuAc2-3  lectin blotting  Saliva, not lung  [60] 
  NeuAc2-6  lectin blotting  lung, saliva  [60] 
  SO3-6GlcNAc  Immunoblotting  Saliva  [63] Int. J. Mol. Sci. 2010, 11                       
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9. Bacteria Binding Sites on DMBT1
SAG 
9.1. Binding Sites on the SRCR Domains 
For DMBT1
 SAG,
 the SRCR domains are identified as bacteria-binding sites. Proteolytic cleavage of 
DMBT1
SAG with Lys-C results in a protein fragment of 1722 amino acids, only containing SRCR 
domains and SIDs, which still binds to S. mutans [65]. The SRCR domains in this protein fragment 
show a high degree of homology, which justifies the design of a consensus sequence. Based on this 
consensus  sequence,  synthetic  peptides  were  designed  consisting  of  the  fragments  between  the 
cysteine residues covering the full SRCR domain and SID fragments. Bacterial binding was restricted 
to  a  16-mer  peptide  (QGRVEVLYRGSWGTVC)  representing  the  second  fragment  in  the  SRCR 
domain and therefore named SRCRP2 [65]. This peptide binds S. mutans and a number of other 
bacterial  species  including  Streptococcus  gordonii,  Staphylococcus  aureus,  Escherichia  coli  and 
H. pylori  [66].  Bacterial  adhesion  to  the  peptide  correlates  with  adhesion  to  the  full  molecule  
(Figure 2) [67].  
Figure 2. Correlation between bacteria binding to DMBT1
SAG and SRCRP2 [67]. 
 
N- and C-terminal truncation resulted in an 11-mer peptide still able to bind bacteria, therefore 
named DMBT1 pathogen binding site 1 (DMBT1pbs1) [66]. Although bacterial binding within the 
SRCR domains  is  only  restricted to the 11-mer peptide, within the peptide different  residues  are 
essential for binding of different bacteria. Alanine scanning analysis demonstrated that eight residues 
out of 11 were involved in binding of different bacterial species (GRVEVLYRGSW). Of these eight 
residues,  four  were  always  present  in  the  binding  motif  (GRVEVLYRGSW).  Of  the  14  SRCR 
domains in the full length molecule, 12 contain the eight amino acids involved in binding giving Int. J. Mol. Sci. 2010, 11                       
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bacterial binding of DMBT1 a multivalent character. One of the two deviating SRCR domains is the 
14th SRCR domain (GRVEIYHGGTW), located between two CUB domains and as such probably not 
involved in bacterial binding.  
SRCR domains in other proteins have previously been implicated in bacteria binding [68–70]. The 
bacteria binding site locates in a similar region of the group A SRCR domains in MARCO, which is a 
macrophage receptor recognizing bacterial surface components such as LPS and LTA. In this case, an 
RXR-motif,  adjacent  to  the  SRCRP2  peptide  motif,  is  responsible  for  bacterial  interactions 
(GSSNRGRAEVYYSG) [71,72]. Similarly, the bacteria binding sites in human Spand CD6, both 
group  B  members  of  the  SRCR  superfamily  that  are  expressed  by  lymphoid  macrophages  and 
lymphocytes, are also located in the SRCR domain. [73,74]. CD 163 (M130), a macrophage receptor 
only consisting of nine SRCR domains, also binds bacteria. Peptides homologous to the DMBT1
SAG 
bacteria binding site were synthesized for all nine SRCR domains and tested for bacteria binding [75]. 
One of these nine peptides, of SRCR domain 3, showed good binding to bacteria (GRIEIKFQGRW).  
9.2. Binding Sites on the Glycan Chains 
Studies  of  bacterial  binding  sites  on  SAG  were  first  mainly  focused  on  carbohydrate  ligands, 
following  the  concept  that  bacteria  primarily  recognize  carbohydrate  ligands  on  mucosal  
surfaces  [76,77].  These  studies  revealed  that  DMBT1
SAG-mediated  agglutination  of  S.mutans  is 
inhibited by high concentrations of fucose and lactose. In line with these results, it was shown that the 
Le
a-antigen (Galβ1, 3(Fucα1, 4)GlcNAc) was involved in S.mutans binding, harboring an essential 
role for the terminal fucose [13]. Other studies demonstrated that sialic acid plays a role in binding of 
DMBT1
SAG to S. sanguis and S. mutans [52,78]. H. pylori can bind Le
b structures and sialic acid on 
DMBT1
SAG with its BabA and SabA adhesins, respectively [64].  
10. DMBT1
SAG Binding Sites on Bacteria 
10.1. Antigen I/II Polypeptides 
DMBT1
SAG was first described as an agglutinating agent for S.mutans and other streptococci [12]. 
Several studies have underlined the importance of bacterial agglutination in the protection against 
dental caries [9,79–81]. High concentrations of DMBT1
SAG on the dental surface promoted S. mutans 
colonization, but high concentrations in saliva inhibit its colonization [80].  
DMBT1
SAG binds in a calcium-dependent manner to antigen I/II polypeptides, a group of surface 
receptors on S. mutans and related streptococci. Antigen I/II polypeptides have been characterized 
under different names in a variety of streptococci, S. mutans (antigen B, P1, Pac, SpaP, MSL-1),  
S. sobrinus (PAg, SpaA), S. gordonii (SspA, SspB), S. intermedius (Pas), S. pyogenes (aspA) and  
S.  agalactiae  (bspD)  [82,83].  Antigen  I/II  polypeptides  on  oral  streptococci  have  been  studied 
extensively  as  candidates  for  vaccine  development  [84].  These  polypeptides,  between  826  and  
1653 amino acids long, share a common primary sequence (Figure 3). All proteins start with a 38 
amino acid (aa) leader sequence that is cleaved off during secretion. The A-region, containing one to 
four copies of an 82 aa residues alanine-rich sequence, is found 165 aa residues downstream of this 
leader. This is followed by a variable region (V-region) and then by a proline-rich P-region containing Int. J. Mol. Sci. 2010, 11                       
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one to three copies of a 39 residue sequence block. The C-terminal region of about 615 amino acids 
shows 64% or more sequence homology between the I/II polypeptides.  
Figure 3. Schematic overview of the structural organization of antigen I/II polypeptides. 
All proteins contain a 38 residues leader peptide. 165 amino acid residues downstream of 
the  leader  peptide  is  the  alanine-rich  region  containing  1–4  repeats  of  an  82  residues 
alanine-rich repeat. This is followed by a variable (V) region, followed by proline-rich P 
region  containing  1–3  copies  of  a  39  residues  repeat.  The  C-terminus  shows  ≥64% 
homology along the antigen I/II protein family. C-terminally is the cell wall anchoring 
sequence (CWA).  
 
Table 3. Binding sites for DMBT1
SAG on various proteins. 
Protein   Sequence   SRCRP2 binding  Ref. 
S.mutans antigen I/II  PQLKTADLPAGRDETTSFVLV    [85] 
S.gordonii antigen I/II 
S.mutans antigen I/II 
ELKTEALTAGRPKTTSFVLV 
QLKTADLPAGRDETTSFVLV 
  [86] 
S.gordonii SspB 390-402 
S.gordonii SspB 390-
T400K-402 
DYQAKLAAYQTEL DYQAKLAAYQKEL 
 
+ 
+ 
 
[87] 
 
 
SsP(A4K-A11K) 
Consensus SspA and B 
DYQKKLAAYQKEL 
DYQAKLAAYQAEL 
+ 
+ 
[88] 
Bovine lactoferrin 480-492  SCAFDEFFSQSCA  +  [89,90] 
Human lactoferrin   DCKFDEYFSQSCA    [91] 
Human casein  LLNQELLNPTHQIYPVTQPLAPVHNPISV    [91] 
HIV V3 region   CTRPNYNKRKR    [92] 
A number of putative binding sites for DMBT1
SAG were identified on antigen I/II polypeptides  
and  other  proteins  (Table  3).  Insight  has  come  from  the  elucidation  of  the  tertiary  structure  of  
antigen  I/II  [83,93].  The  V-region  of  Ag  I/II  polypeptides  may  adopt  a  lectin-like  conformation, 
supporting  the  suggestion  that  antigen  I/II  polypeptides  bind  to  DMBT1
SAG  by  recognition  of 
carbohydrate moieties [94]. This V-region is projected from the cell surface by a stalk formed by an 
association between an N-terminal α-helix of the alanine-rich repeats and a C-terminal polyproline 
helix.  The  C-terminus  of  antigen  I/II,  which  is  in  close  vicinity  to  the  cell  surface,  also  binds 
DMBT1
SAG [85,93]. A synthetic 20-mer peptide, corresponding to residues 1025-1044 of antigen I/II 
(PQLKTADLPAGRDETTSFVLV),  inhibited  binding  to  DMBT1
SAG  and  selectively  inhibited 
colonization of S.mutans to the tooth surface [85]. The presence of two binding sites for DMBT1
SAG 
may  also  explain  the  intriguing  observation  that  streptococcal  binding  to  surface  immobilized 
DMBT1
SAG is different from binding to DMBT1
SAG in solution [95,96]. Overlapping, but not identical, 
subsets  of  monoclonal  antibodies  against  antigen  P1  inhibited  SAG  mediated  adherence  and Int. J. Mol. Sci. 2010, 11                       
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aggregation, indicating that in the adsorbed state, other domains were involved in the interaction with 
bacteria than in the soluble phase. Furthermore, DMBT1
SAG in solution and adsorbed DMBT1
SAG 
were differentially recognized by streptococci, which formed three phenotypic groupings according to 
their modes of interaction: one group binding to both surface-bound and soluble DMBT1
SAG, one 
group  binding  only  to  surface-bound  SAG,  and  one  group  interacting  preferentially  with  soluble 
DMBT1
SAG [95]. Deletion of antigen I/II polypeptides in S. gordonii reduced adhesion to immobilized 
DMBT1
SAG by 40%, while deletion of Hsa—another streptococcal surface antigen—reduced adhesion 
by 80%. In contrast, aggregation by DMBT1
SAG disappeared after deletion of antigen I/II polypeptides 
but was not affected by deletion of Hsa [97].
 The differences in binding between absorbed and soluble 
state is not unique to DMBT1
SAG, and has been reported for the protein-bacterial interaction between 
Actinomyces viscosus and acidic proline rich proteins as well as statherin. A. viscosus only bound to 
surfaces coated with these proteins, but not to the same proteins in solution. [98,99]. This is attributed 
to a conformational change which takes place when the proteins are adsorbed onto a surface, resulting 
in the exposure of previously hidden bacterial receptors, cryptitopes. Statherin is a peptide which in 
solution  has  no  defined  tertiary  structure.  Upon  adsorption  onto  a  hydroxyapatite  surface,  
the  C-terminal  region  folds  into  a  α-helical  conformation,  which  is  recognized  by  bacterial 
receptors [100]. Conclusive evidence for differences in soluble and surface bound DMBT1
SAG remains 
to be demonstrated by identifying the epitopes that are exposed only on immobilized DMBT1
SAG 
compared to soluble DMBT1
SAG, and vice versa. 
10.2. Pathogen Associated Molecular Patterns 
Bacteria that do not possess antigen I/II polypeptides, like H. pylori and Staphylococcus aureus, 
also bind DMBT1
SAG [22,65]. CRP-ductin, the mouse homolog of DMBT1, bind to several Gram
+ and 
Gram
- bacteria, including Haemophilus influenzae, Klebsiella oxytoca, S. aureus and Streptococcus 
pneumoniae [101]. As many SRCR proteins are pattern recognition receptors, DMBT1
SAG might also 
recognize common motifs on pathogens, so–called PAMPs (pathogen associated molecular patterns). 
DMBT1
SAG binds to lipoteichoic acid, a component on the membrane of Gram-positive bacteria, and 
to lipopolysaccharide (LPS), a common component on the cell membrane of Gram-negative bacteria. 
LPS has been found to bind to SRCRP2, suggesting DMBT1 recognizes LPS with its SRCR domains 
[102]. Binding studies to truncated variants of LPS from Salmonella showed that binding depended on 
the availability and accessibility of phosphorylated structures on LPS. In addition, sulfated substances 
such as dextran sodium sulfate (DSS) and the food stabilizer carrageenan also bound to DMBT1. DSS 
is used to induce colitis in mice in a disease model for ulcerative colitis. In a DSS-induced colitis 
model, Dmbt1
-/- mice were more susceptible to low doses of DSS than Dmbt1
+/+ mice. However, since 
this is a commensal bacteria induced colitis model, this effect is likely to be attributed to Dmbt1’s 
ability to control the natural intestinal microflora.  
11. Interaction with Viruses  
Besides bacteria, DMBT1
SAG also binds viruses, including HIV-1 [92,103] and influenza A virus 
[60,104].  HIV-1  infects  host  cells  by  binding  to  the  CD4  receptor  through  the  viral  envelope 
glycoprotein gp120, which leads to conformational changes in gp120 allowing high affinity interaction 
with  chemokine  receptors  [105,106].  DMBT1
SAG  shows  a  calcium-dependent  interaction  with  the Int. J. Mol. Sci. 2010, 11                       
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virus  gp120.  The  DMBT1
SAG  binding  region  on  gp120  is  localized  to  a  linear,  highly  conserved 
sequence (CTRPNYNKRKR) near the stem of the V3 loop that is critical for chemokine receptor 
interaction during viral binding and infection [92]. Thus, DMBT1
SAG most probably blocks the access 
of gp120 to the chemokine receptor. The N-terminal sequence of DMBT1, including the first SRCR 
domain  and  one-half  of  the  first  SID,  binds  in  a  Ca
2+-dependent  manner  to  the  same  HIV-1  V3 
sequences previously identified to interact with full-length SAG [107].  
DMBT1
SAG and DMBT1
GP340 also inhibit the hemagglutination activity and infectivity of Influenza 
A  virus  (IAV)  [104],  which  is  responsible  for  outbreaks  of  influenza.  IAV  infects  cells  of  the 
respiratory tract by binding to sialic acid residues present at the cell surface. Different influenza strains 
recognize specifically (2,3)-linked or (2,6)-linked sialic acid. DMBT1
 has broad antiviral activity 
against human, equine and porcine IAV strains by sialic acid mediated binding to IAV, which results 
in  virus  neutralization  [60].  A  variant  of  DMBT1
SAG  had  significantly  greater  inhibitory  activity 
against  avian-like  IAV  strains  which  preferentially  bound  sialic  acids  in  (2,3)  linkage,  than 
DMBT1
SAG from another donor or three lung preparations of DMBT1
GP340 [60]. In line with this, a 
greater  density  of  (2,3)-linked  sialic  acids  was  present  on  the  DMBT1
SAG  from  this  donor  as 
compared with the other samples. Hence, the specificity of sialic acid  linkages on DMBT1 is  an 
important determinant of anti-IAV activity. In addition to these direct virus-neutralizing properties, 
DMBT1
GP340  displays  cooperative  interactions  with  SP-D  in  viral  neutralization  and  aggregation 
assays. On the other hand, in some cases DMBT1
SAG strongly antagonizes the antiviral activities of 
SP-D by binding to its carbohydrate recognition domain, which is involved in virus binding [60].  
12. Interaction with Endogenous Protein Ligands  
DMBT1 binds to a number of endogenous proteins such as secretory IgA, MUC5B, surfactant 
proteins  A  and  D,  complement  factor  C1q,  lactoferrin  and  albumin  [16–18,21,25,89,108,109]. 
DMBT1
SAG binds to secretory IgA in a calcium-dependent manner, resulting in a cooperative effect on 
bacterial aggregation [15,110]. Binding of DMBT1
SAG to IgA is mediated by the same 11-mer peptide 
that  is  responsible  for  the  broad-spectrum  bacteria  binding  of  DMBT1
SAG  [18].  Binding  of  a 
DMBT1
SAG-IgA complex to the Pac molecule of S. mutans was demonstrated [52]. After chemical 
reduction, this complex was dissociated into sIgA and DMBT1
SAG and concomitantly binding to Pac 
disappeared.  
DMBT1
SAG also binds to C1q of the complement system, a system of plasma proteins that may 
react with one another to opsonize or permeabilize pathogens and induce a series of inflammatory 
responses [109]. By binding of SAG to C1q, the complement system is activated through the classical 
pathway [16]. Although DMBT1
SAG is secreted in saliva and C1q is a serum component, these two 
fluids may mix in the oral cavity under conditions of oral inflammation, e.g., periodontal disease, or 
mucosal damage, thus enabling a local complement activation.  
DMBT1
 also binds to bovine and human lactoferrin, an 80 kDa iron binding protein belonging to 
the transferrin family [17,19]. Lactoferrin exhibits various functions in the innate immune system. It 
sequesters  iron  from  the  local  environment  thus  inhibiting  microbial  growth  and  it  prevents  the 
formation  of  Pseudomonas  biofilms  [111].  In  addition,  antimicrobial  peptides  are  released  upon 
proteolytic  degradation  of  lactoferrin  [112].  Bovine  lactoferrin  inhibits  DMBT1
SAG  binding  to 
S. mutans protein antigen Pac, which belongs to the antigen I/II family [17]. The SRCRP2 peptide of Int. J. Mol. Sci. 2010, 11                       
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DMBT1
SAG that is responsible for S. mutans binding also mediates binding of lactoferrin [17,89]. 
Bovine  lactoferrin  residues  480–492  (SCAFDEFFSQSCA)  are  important  for  DMBT1
SAG  binding. 
Although the homologous sequence in human lactoferrin is slightly different (SCKFDEYFSQSCA), 
human lactoferrin also binds to DMBT1 [19]. 
 
DMBT1
GP340,  which  originally  was  isolated  as  a  soluble  receptor  for  SP-D,  also  binds  
SP-A  [20,25].  SP-A  and  SP-D  are  collagen-containing  (C-type)  calcium-dependent  lectins  called 
collectins [113]. SP-D forms oligomers of 4–8 subunits. Each subunit is composed of three identical 
polypeptides  of  43  kDa  held  together  by  disulfide  bonds  and  non-covalent  interactions  at  the  
N-terminal ends of the chains. Each polypeptide consists of a short N-terminal region, followed by a 
collagen-like  sequence,  a  short  -helical  sequence  and  the  carbohydrate  recognition  domain. 
DMBT1
GP340 binds to the carbohydrate recognition domain of SP-D through a calcium-dependent 
protein-protein  interaction  [20].  SP-A  and  SP-D  are  involved  in  a  range  of  immune  functions 
including viral neutralization, aggregation and killing of bacteria and fungi, and clearance of apoptotic 
and necrotic cells.  
13. Role of DMBT1 in Innate Immunity 
Due to their broad pathogen binding spectrum, DMBT1 and its mouse homolog CRP-ductin are 
considered pattern recognition receptors (PRRs) [101], an ancient germline encoded defense system 
against pathogen invasion in both plants and animals [114,115]. PRRs recognize conserved structures 
of  the  microbial  cell  that  are  vital  for  survival,  so–called  pathogen-associated  molecular  patterns 
(PAMPs). PAMPs include mannans and zymosan of the yeast cell wall, various bacterial cell-wall 
components, such as lipoteichoic acid (LTA) of Gram-positive bacteria or lipopolysaccharide (LPS) of 
Gram-negative  bacteria,  and  bacterial  DNA  [116,117].  In  the  human  body,  PRRs  are  found  on  
host–pathogen interacting surfaces and expressed by epithelial cells, macrophages, granulocytes and 
dendritic cells or as secretory products present in mucosal fluids [115,118]. These characteristics are 
also applicable to DMBT1. PRRs form a diverse group of proteins including mannose-binding lectin, 
collectins,  CD14,  Toll-like  receptors  and  Nucleotide-binding  oligomerization  domain  (Nod)  
proteins [70,115,119,120]. The SRCR proteins SR-AI and
 SR-AII, MARCO and Sp, alsobelong to 
this group.  
14. Conclusions 
Conclusively, DMBT1 plays a role in innate immunity by binding to a large panel of exogenous 
and endogenous ligands. SRCRP2 on the SRCR domains and sialic acids on the glycan chains have 
been identified as ligand binding sites, but DMBT1 may harbor many other potential ligand binding 
sites. These many ligand binding sites and its structural heterogeneity—both in the different tissues 
and between different individuals—are only two of the many surprises hidden in this molecule. Future 
research  should  focus  on  the  precise  role  of  DMBT1  in  the  innate  immune  system  and  the 
physiological consequences of its heterogeneity.  Int. J. Mol. Sci. 2010, 11                       
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